losartan has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chamseddine, S; Gu, L; Huang, JY; Karin, M; Kaseb, AO; Lee, M; Mohamed, YI; Nguyen, A; Pandit, SK; Ryujin, NT; Shalapour, S; Xiao, L; Zhu, Y | 1 |
| Diz-Muñoz, A; Freire Valls, A; Imle, A; Liang, J; Lu, J; Muley, T; Radhakrishnan, P; Ruiz de Almodovar, C; Salfenmoser, M; Schleussner, N; Schmidt, T; Schneider, M; Shen, Y; Wang, G; Wang, X; Wirsik, NM | 1 |
| Akahane, T; Ishida, K; Kaji, K; Kawaratani, H; Mitoro, A; Moriya, K; Namisaki, T; Nishimura, N; Ogawa, H; Takagi, H; Takaya, H; Yoshiji, H | 1 |
3 other study(ies) available for losartan and Cancer of Liver
| Article | Year |
|---|---|
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Cirrhosis; Liver Neoplasms; Losartan; Non-alcoholic Fatty Liver Disease | 2023 |
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bevacizumab; Cancer-Associated Fibroblasts; Captopril; Colorectal Neoplasms; Drug Synergism; Humans; Liver Neoplasms; Losartan; Lung Neoplasms; Neovascularization, Pathologic; Renin-Angiotensin System; Tumor Microenvironment | 2020 |
The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cytostatic Agents; Humans; Liver Neoplasms; Losartan; Mice; Phenylurea Compounds; Quinolines | 2021 |